Trial
NCT00750919
Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Merck Sharp & Dohme LLC
Collaborators
—
Condition
Sleep Initiation and Maintenance Disorders
Intervention
esmirtazapine
Why stopped
This trial was stopped prematurely due to the Sponsor's decision not to continue the development of esmertazapine for this indication.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-02-02